Erasca, Inc. develops precision oncology therapies for cancers driven by the RAS/MAPK pathway. News on ERAS commonly centers on its RAS-targeting pipeline, including ERAS-0015, an investigational oral pan-RAS molecular glue evaluated in RAS-mutant solid tumors, and ERAS-4001, an oral pan-KRAS inhibitor for KRAS-mutant solid tumors.
Company updates frequently cover Phase 1 clinical data, dose-escalation results, trial collaborations and supply agreements, intellectual-property protection, development rights, public offering activity, financial results, and healthcare conference presentations. Recurring cancer settings in company disclosures include non-small cell lung cancer, pancreatic adenocarcinoma, colorectal cancer, and other RAS-mutant solid tumors.
Erasca (Nasdaq: ERAS) announced that the U.S. Patent and Trademark Office issued Patent No. 12,458,647, titled “Macrocyclic Derivative And Use Thereof,” covering the composition of matter for the pan‑RAS molecular glue ERAS-0015 and related compositions.
The patent provides protection through September 2043, subject to possible patent term adjustments or extensions. The company noted it in‑licensed the program in May 2024 and said initial Phase 1 monotherapy data for ERAS-0015 and for pan‑KRAS inhibitor ERAS-4001 are expected in 2026.
Erasca (Nasdaq: ERAS) announced management will participate in investor conferences and one-on-one meetings in November 2025. Events and times:
- Guggenheim 2nd Annual Healthcare Innovation Conference — Boston, Nov 10-12; Fireside chat on Nov 11 at 2:00 pm ET.
- Stifel 2025 Healthcare Conference — New York, Nov 11-13; Fireside chat on Nov 12 at 1:20 pm ET.
- Jefferies Global Healthcare Conference — London, Nov 17-20; Fireside chat on Nov 19 at 10:30 am GMT.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancer therapies, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, September 9, 2025, at 3:20 PM ET at the Sheraton New York Times Square and engage in one-on-one investor meetings.
Investors can access a live audio webcast of the presentation through Erasca.com/events, with a replay available for 30 days following the event.
Erasca (Nasdaq: ERAS), a precision oncology company, reported significant progress in its RAS-targeting cancer therapy development program and Q2 2025 financial results. The company achieved key milestones with FDA clearance for two investigational new drug (IND) applications: ERAS-4001 (pan-KRAS inhibitor) and ERAS-0015 (pan-RAS molecular glue), both targeting RAS-mutant solid tumors.
The company maintains a strong financial position with $386.7 million in cash and equivalents as of June 30, 2025, expected to fund operations into H2 2028. Q2 2025 saw reduced losses with a net loss of $33.9 million ($0.12 per share), compared to $63.2 million ($0.29 per share) in Q2 2024. Initial Phase 1 monotherapy data for both drug candidates is expected in 2026.
Erasca (NASDAQ: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancer therapies, has announced its participation in two major investor conferences in June 2025:
1. Jefferies Global Healthcare Conference (June 3-5) in New York, featuring a fireside chat on June 4 at 5:30 PM ET
2. Goldman Sachs 46th Annual Global Healthcare Conference (June 9-11) in Miami Beach, with a fireside chat scheduled for June 10 at 2:40 PM ET
Management will participate in one-on-one investor meetings at both conferences. Live audio webcasts will be available at Erasca.com/events, with replays accessible for 30 days after each event.
Erasca (NASDAQ: ERAS), a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, has announced its participation in the Bank of America Securities 2025 Health Care Conference. The event will take place at the Encore Hotel in Las Vegas, Nevada. The company's management will deliver a presentation on Wednesday, May 14, 2025, at 2:35 PM Pacific Time and will engage in one-on-one investor meetings. A live audio webcast will be accessible at Erasca.com/events, with a replay available for 30 days following the presentation.
Erasca presented new preclinical data at the 2025 AACR Annual Meeting, highlighting advances in their RAS-targeting cancer therapy franchise. The company showcased two key compounds:
ERAS-0015, a pan-RAS molecular glue, demonstrated:
- 8-21 times greater cyclophilin A binding versus competitor RMC-6236
- Strong anti-tumor activity at lower doses
- Effective tumor tissue distribution
ERAS-4001, a novel pan-KRAS inhibitor, showed:
- Selective targeting of both mutant and wildtype KRAS
- Strong tumor growth inhibition in multiple models
- Promising results when combined with anti-PD-1 or cetuximab
Additionally, the company identified first-in-class direct SHOC2 binders, representing a new approach to block cancer-causing RAS/MAPK pathway signaling. These developments reinforce Erasca's position in precision oncology for RAS/MAPK pathway-driven cancers.